Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-26T00:46:23.409Z Has data issue: false hasContentIssue false

Comorbidity in Schizophrenia

Published online by Cambridge University Press:  16 April 2020

A. Chinchilla
Affiliation:
Hospital Ramón y Cajal, University of Alcalá de Henares, Madrid, Spain
M. Vega
Affiliation:
H. Ramón y Cajal, Madrid, Spain
A. Cebollada
Affiliation:
H. Ramón y Cajal, Madrid, Spain
T. Alvarez
Affiliation:
H. Ramón y Cajal, Madrid, Spain
M. Gómez
Affiliation:
H. Ramón y Cajal, Madrid, Spain
F. Pando
Affiliation:
H. Ramón y Cajal, Madrid, Spain
C. Erausquin
Affiliation:
H. Ramón y Cajal, Madrid, Spain
R. Martinez de Velasco
Affiliation:
H. Ramón y Cajal, Madrid, Spain
D. De La Vega
Affiliation:
H. Ramón y Cajal, Madrid, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

The coexistence of comorbidity in schizophrenia (somatic, dual pathology, personality…) can conditionate evolution and prognosis in this severe mental illness, those aspects should be taken in account to planify treatments and follow up issues.

Objective:

We are interested in this work in evaluate previous and developed comorbidity in schizophrenic patients; we also analyzed comorbidity consequences in clinical, therapeutical management, treatment adherence, relapses and hospitalizations.

Material and method:

In 50 Schizophrenic patients (DSM-IV TR Diagnostic criteria) with at least one previous psychotic episode we have studied longitudinal and transversally sociodemographic, clinical and therapeutical variables, related comorbidity (somatic, drugs related and dual pathology) and evolution, prognosis, clinical, treatment adherence and tolerance variables were also studied. We also evaluate psychopathologic and medical status (EEG, EKG, Chest RX, BMI, body weight, general analysis) secondary effects were registered. Uxue and CGI were the scales used.

Results:

Between 20% and 25% had other medical conditions, and 25-30% had some kind of drug abuse, those were who had worse prognosis, more secondary effects and usually were treated with classic antipsychotics.

Conclusions:

The results are discussed, and we propose integrative treatments for schizophrenia and the co morbidities, focusing on affectivity and tolerance.

Type
P03-214
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.